A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

Phase 1 Completed 40 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.

Timeline

Start: 2005-03-17
Primary completion: 2008-05-13
Completion: 2011-08-29

Publications

Background Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Foretinib	Small molecule	0.1 mg/kg	Oral
Subject	Foretinib	Small molecule	20 mg	Oral
Subject	Foretinib	Small molecule	100 mg	Oral
Subject	Foretinib	Small molecule	200 mg	Oral
Subject	Foretinib	Small molecule	250 mg	Oral
Subject	Foretinib	Small molecule	1000 mg	Oral

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications